2.2.4.4-Tetramethyl-pentylamin | 32905-78-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2.2.4.4-Tetramethyl-pentylamin
• 英文别名: 2,2,4,4-Tetramethylpentylamin；2,2,4,4-Tetramethylpentan-1-amine
• CAS: 32905-78-5
• 化学式: C₉H₂₁N
• mdl: MFCD00467969
• 分子量: 143.272
• InChiKey: VYGCSTNMRUGBRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2,2,4,4-tetramethyl-valeric acid amide 在 lithium aluminium tetrahydride 、 phosphorus pentoxide 作用下， 以 乙醚 为溶剂， 生成 2.2.4.4-Tetramethyl-pentylamin
  参考文献：
  名称：

  Lespagnol,A. et al., Chimica Therapeutica, 1971, vol. 6, p. 208 - 214

  摘要：

  DOI：

文献信息

• Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof
  申请人：Unoki Gen

  公开号：US20070173519A1

  公开（公告）日：2007-07-26

  A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or tumor growth.

  由式（1）表示的吡唑吡嘧啶衍生物及其药用盐对MAPKAP-K2表现出优异的抑制活性。因此，含有该化合物作为活性成分的药物预计对治疗由MAPKAP-K2介导的疾病，如炎症性疾病、自身免疫疾病、破坏性骨病、癌症和/或肿瘤生长等方面具有有效性。
• [EN] LIPOSOME FORMULATION<br/>[FR] FORMULATION DE LIPOSOMES
  申请人：ROSI CHARNI AS

  公开号：WO2020251368A1

  公开（公告）日：2020-12-17

  The present invention describes liposome formulations comprising a phospholipid, cholesterol and a fatty acid compound or fatty acid containing compound. Also, various medical uses of the liposome formulation are described.

  本发明描述了包含磷脂、胆固醇和脂肪酸化合物或含脂肪酸的化合物的脂质体配方。此外，还描述了脂质体配方的各种医疗用途。
• Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof
  申请人：Unoki Gen

  公开号：US20070072898A1

  公开（公告）日：2007-03-29

  A pyrazolo[1,5-a]pyridine derivative represented by formula (I) and salt thereof exhibit excellent MAPKAP-K2 inhibitory activity. Accordingly, medicines comprising this compound as an active ingredient are expected to be valuable for treating or preventing diseases mediated by MAPKAP-K2 such as inflammatory injury, autoimmune diseases, asteropathia destruens, cancer and/or growth of tumor.

  由式(I)表示的吡唑并[1,5-a]吡啶衍生物及其盐表现出优异的MAPKAP-K2抑制活性。因此，包含该化合物作为活性成分的药物预计对治疗或预防由MAPKAP-K2介导的疾病，如炎症损伤、自身免疫疾病、asteropathia destruens、癌症和/或肿瘤生长具有重要价值。
• HIGH REFRACTIVE INDEX ACRYLIC COMPOUND AND METHOD FOR PREPARING THE SAME
  申请人：SAMSUNG SDI CO., LTD.

  公开号：US20150368280A1

  公开（公告）日：2015-12-24

  An acrylic compound is represented by Formula 1. In Formula 1, R 1 and R 2 are each independently a C 2 to C 10 alkylene group, a C 6 to C 20 arylene group, a C 7 to C 20 alkylarylene group, or a C 7 to C 20 arylalkylene group. Ar 1 is a C 6 to C 10 aryl group. X 1 and X 2 are each independently —O— or —S—. Y 1 and Y 2 are each independently a hydrogen atom, —OH, —SH, —NH 2 , and at least one of Y 1 and Y 2 is n 1 , n 2 , n 3 and n 4 are each independently 1 to 4 on average. The acrylic compound includes no halogen atoms and has a high refractive index of about 1.65 or greater.

  一种丙烯酸化合物由公式1表示。在公式1中，R1和R2分别独立地为C2到C10烷基，C6到C20芳基，C7到C20烷基芳基或C7到C20芳基烷基。Ar1是C6到C10芳基。X1和X2分别独立地为—O—或—S—。Y1和Y2分别独立地为氢原子，—OH，—SH，—NH2，且Y1和Y2中至少有一个为n1，n2，n3和n4分别独立地为1到4，平均值为1. 该丙烯酸化合物不含卤素原子，具有大约1.65或更高的高折射率。
• Immunomodulating Heterocyclic Compounds
  申请人：Matthews Richard Ian

  公开号：US20080045527A1

  公开（公告）日：2008-02-21

  Compounds of formula (I) are inhibitors of CD80 and useful in immunomodulation therapy: wherein R 1 and R 3 independently represent H; F; Cl; Br; —NO 2 ; —CN; C 1 -C 6 alkyl optionally substituted by F or Cl; or C 1 -C 6 alkoxy optionally substituted by F; R 4 represents a carboxylic acid group (—COOH) or an ester thereof, or —C(═O)NR 6 R 7 , —NR 7 C(═O)R 6 , —NR 7 C(═O)OR 6 , —NHC(═O)NR 7 R 6 or —NHC(═S)NR 7 R 6 wherein R 6 represents H, or a radical of formula -(Alk) m -Q wherein m is 0 or 1, Alk is an optionally substituted divalent straight or branched C 1 -C 12 alkylene, or C 2 -C 12 alkenylene, or C 2 -C 12 alkynylene radical or a divalent C 3 -C 12 carbocyclic radical, any of which radicals may contain one or more —O—, —S— or —N(R 8 )— links wherein R 8 represents H or C 1 -C 4 alkyl, C 3 -C 4 alkenyl, C 3 -C 4 alkynyl, or C 3 -C 6 cycloalkyl, and Q represents H; —NR 9 R 10 wherein R 9 and R 10 independently represents H; C 1 -C 4 alkyl; C 3 -C 4 alkenyl; C 3 -C 4 alkynyl; C 3 -C 6 cycloalkyl; an ester group; an optionally substituted carbocyclic or heterocyclic group; or R 9 and R 10 form a ring when taken together with the nitrogen to which they are attached, which ring is optionally substituted; and R 7 represents H or C 1 -C 6 alkyl; or when taken together with the atom or atoms to which they are attached R 6 and R 7 form an optionally substituted monocyclic heterocyclic ring having 5, 6 or 7 ring atoms; and X represents a bond or a divalent radical of formula -(Z) n -(Alk)- or -(Alk)-(Z) n - wherein Z represents —O—, —S— or —NH—, Alk is as defined in relation to R 6 and n is 0 or 1.

  式（I）的化合物是CD80的抑制剂，可用于免疫调节治疗：其中R1和R3分别表示H; F; Cl; Br; -NO2; -CN; C1-C6烷基，其可选地被F或Cl取代; 或C1-C6烷氧基，其可选地被F取代; R4表示羧酸基（-COOH）或其酯，或-C（=O）NR6R7，-NR7C（=O）R6，-NR7C（=O）OR6，-NHC（=O）NR7R6或-NHC（=S）NR7R6，其中R6表示H，或式-(Alk)m-Q的基团，其中m为0或1，Alk为可选地取代的二价直链或支链C1-C12烷基，或C2-C12烯基，或C2-C12炔基基团或二价C3-C12环烷基基团，其中任何基团都可以包含一个或多个-O-，-S-或-N（R8）-链接，其中R8表示H或C1-C4烷基，C3-C4烯基，C3-C4炔基，或C3-C6环烷基; Q表示H; -NR9R10，其中R9和R10独立地表示H; C1-C4烷基; C3-C4烯基; C3-C4炔基; C3-C6环烷基; 酯基; 可选地取代的碳环或杂环基团; 或者R9和R10与它们所连接的氮一起形成一个环，该环可选地被取代; R7表示H或C1-C6烷基; 或者当它们所连接的原子或原子与R6一起形成一个可选地取代的含5,6或7个环原子的单环杂环时; X表示键或式-(Z)n-(Alk)-或-(Alk)-(Z)n-的二价基团，其中Z表示-O-，-S-或-NH-，Alk如在关于R6的定义中所述，n为0或1。